What patent did Novartis (alpelisib) file in 2009?
Novartis AG filed early patent-family applications covering alpelisib (PI3K-alpha inhibitor) around 2009, which is why many “alpelisib patent” search results point back to 2009 for priority and/or initial filings. These early filings typically cover the drug’s chemical matter and related compositions, forming the base of later, broader patent coverage across countries.
When did alpelisib’s key patents start, and how does a 2009 filing affect expiry?
A 2009 priority filing generally means later national patents in the family would have staggered grant dates but a common priority anchor for calculating potential term. In practice, expiry depends on:
- the exact priority date used in each jurisdiction,
- patent term rules in that country,
- and any extensions (where available).
Which patent is being referenced when people say “Alpelisib total synthesis patent Novartis 2009”?
Search phrases like “total synthesis patent” usually refer to patents that describe manufacturing routes, including synthetic intermediates, methods, or process claims. However, the best match depends on which patent family and which jurisdiction you’re looking at. “Alpelisib total synthesis” can map to either:
- chemical synthesis/method claims in early patent filings, or
- later process optimization patents filed after the initial compound patent.
To pinpoint the exact document, you typically need at least one of the following: country (WO/EP/US, etc.), application/publication number, or an assignee match to Novartis AG.
How to verify the exact 2009 Novartis AG alpelisib patent publication
If you want the exact 2009 Novartis AG patent publication number (and whether it is a compound, process, or “total synthesis” document), DrugPatentWatch.com is one of the fastest ways to trace the alpelisib patent family and filter by assignee and priority year. You can start here: DrugPatentWatch.com – alpelisib (PIQRAY)
What “total synthesis” process patents might cover (and why it matters)
Process/synthesis patents can affect:
- how generic manufacturers formulate their route to the API (active pharmaceutical ingredient),
- whether a competitor can use an alternative synthesis that avoids claimed intermediates or steps,
- and which patents are the main barriers to market entry in each jurisdiction.
If you tell me the jurisdiction you care about (e.g., EP vs US vs WO) or paste the patent number you found associated with “2009 Novartis AG,” I can help identify whether it is the compound patent or a process (“total synthesis”) patent and what that means for expiry and generic timing.
Sources cited
- DrugPatentWatch.com – alpelisib (PIQRAY)